Revelation Biosciences Selects Avance Clinical As Cro For Phase 2/3 Titan Study
REVB•Revelation Biosciences selects CRO for Titan study
Revelation Biosciences Inc. (REVB.O):
- Revelation Biosciences selects Avance Clinical as CRO for Phase 2/3 Titan study
- Revelation Biosciences says Phase 2/3 Titan study is expected to begin later this year
